RxDoctor Payments Data

Henry Calas, MD

Neurology · Stuart, FLNPI 1871507269

Payments from drug & device makers

$20,340in general payments, 2019–2025

Across 793 payments — averaging $25.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$2K
  • UCB, Inc.$1K
  • Pfizer$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Eisai Inc.$1K
  • plus $12K from 49 others

What the payments were for

  • Speaking & faculty fees$200%
  • Food & beverage$20,22699%
  • Education$940%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,340 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$144,425
Medicare patients
295
Services billed
880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin14$147,347
EpidiolexCannabidiol (Cbd)12$73,714
Nurtec OdtRimegepant Sulfate27$53,798
UbrelvyUbrogepant24$34,464
VimpatLacosamide17$29,992
QuliptaAtogepant16$27,882
ZonegranZonisamide12$26,587
LamictalLamotrigine12$18,229
Aimovig AutoinjectorErenumab-Aooe12$17,553
TrileptalOxcarbazepine13$15,926
Modafinil17$12,267
DepakoteDivalproex Sodium13$8,596
NamzaricMemantine Hcl/Donepezil Hcl11$7,352
Doxepin Hcl40$6,901
Levetiracetam83$3,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$933$147,34714 claims
AbbVieUbrelvy, Qulipta, Namzaric$2,191$69,69751 claims
PfizerNurtec Odt$1,184$53,79827 claims
UCB, Inc.Vimpat$1,388$29,99217 claims
Upsher-smith Laboratories LLCTopiramate$369$1,56782 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →